Loading asset research
Q3 2026 earnings · Nov 5
LB Pharmaceuticals Inc Common Stock
LBRXNasdaq · USD · StocksQuote as of · Exchange session not verified$37.32
-4.49%
Today
LBRX
Loading 1D prices…
Market cap
$1.2B
Volume
413.5K
52w high
$50.1652w low
$13.36Company profile
LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
49
Fiscal year end
1231
CIK
1691082
Session & valuation
Open$39.13
Previous close$39.19
Day high$39.39
Day low$37.56
30-day avg. volume299.6K
Outstanding shares32.3M
Diluted EPS-$3.13
Latest annual period
P/E (trailing)-11.92
P/E (forward)-7.51
Price / book3.26
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| OPKOPKO Health Inc. Common Stock | $1.2B | $606.9M | -37186.98% | -$0.30 | -2.94% | Buy |
| HROWHarrow Inc. Common Stock | $1.2B | $272.3M | -1.89% | -$0.14 | -1.34% | Buy |
| DMRADamora Therapeutics Inc. Ordinary Shares | $1.3B | $0.00 | — | $3.98 | +1.13% | Buy |
| LTGOLatigo Biotherapeutics Inc. Common Stock | $1.2B | $0.00 | — | -$2.48 | -11.07% | Buy |
| AVLNAvalyn Pharma Inc. Common Stock | $1.3B | $0.00 | — | -$2.04 | -3.77% | Buy |